ライフサイエンスコーパス: beta-2 adrenergic receptor

1 ugh it attenuated the resensitization of the beta 2-adrenergic receptor.

2 uced metastasis through up-regulation of the beta-2 adrenergic receptor.

3 eine residue (C607) after stimulation of the beta(2) adrenergic receptor.

4 nges in the G protein-coupling domain of the beta(2) adrenergic receptor.

5 first study of CB2 based on the structure of beta(2)-adrenergic receptor.

6 late two different GPCRS: rhodopsin, and the beta(2)-adrenergic receptor.

7 containing transferrin and agonist-activated beta(2)-adrenergic receptor.

8 ion and trafficking of the G protein-coupled beta(2)-adrenergic receptor.

9 the internalization of the Galpha(s)-coupled beta(2)-adrenergic receptor.

10 ia coli rhomboid protease GlpG and the human beta(2)-adrenergic receptor.

11 geneity of the liganded states formed by the beta(2)-adrenergic receptor.

12 hosphatases, associating reversibly with the beta(2)-adrenergic receptor.

13 l as insulin-stimulated sequestration of the beta(2)-adrenergic receptor.

14 pid phosphorylation and sequestration of the beta(2)-adrenergic receptor.

15 plicating Akt in downstream signaling to the beta(2)-adrenergic receptor.

16 MP generation elicited by stimulation of the beta(2)-adrenergic receptor.

17 ts ability to promote internalization of the beta(2)-adrenergic receptor.

18 udes insulin-stimulated sequestration of the beta(2)-adrenergic receptor.

19 l as insulin-stimulated sequestration of the beta(2)-adrenergic receptor.

20 tes clathrin-mediated internalization of the beta(2)-adrenergic receptor.

21 nt mutants to inhibit internalization of the beta(2)-adrenergic receptor.

22 of TM3 and TM6 in the inactive state of the beta(2)-adrenergic receptor.

23 nal reported after agonist occupation of the beta(2)-adrenergic receptor.

24 of Glu-268(6.30) and of Asp-130(3.49) in the beta(2)-adrenergic receptor.

25 tly blocks the ability of gravin to bind the beta(2)-adrenergic receptor.

26 in, as well as enhanced sequestration of the beta(2)-adrenergic receptor.

27 he known interaction involving Ser204 of the beta(2)-adrenergic receptor.

28 ant D2 dopamine receptor and the beta(1) and beta(2) adrenergic receptors.

29 s desensitization and down-regulation of the beta(2)-adrenergic receptors.

30 cells to apoptosis through interaction with beta(2)-adrenergic receptors.

31 bligate for resensitization and recycling of beta(2)-adrenergic receptors.

32 protein kinase B) in the internalization of beta(2)-adrenergic receptors.

33 dilated cardiomyopathy model overexpressing beta(2)-adrenergic receptors.

34 analyze agonist-dependent internalization of beta(2)-adrenergic receptors.

35 e we propose an activation mechanism for the beta(2)-adrenergic receptor, a prototypical GPCR, based

36 central structural feature in the ECS of the beta(2) adrenergic receptor: a salt bridge linking extra

37 We propose that the beta(2)-adrenergic receptor activates Src via two indepe

38 at Thr-382 and becomes dephosphorylated upon beta(2)-adrenergic receptor activation in COS-1 cells.

39 es revealed abnormal cAMP accumulation after beta(2)-adrenergic receptor activation in PI3Kgamma(-/-)

40 the beta(2)-adrenergic receptor, even though beta(2)-adrenergic receptor activation promoted tyrosyl

41 tosidase (adeno-beta-gal, n=11) or the human beta(2)-adrenergic receptor (adeno-beta(2)-AR, n=15) wer

42 Beta-2 adrenergic receptor (ADRB2) is the primary target

43 IC1 is a direct transcriptional repressor of beta-2 adrenergic receptor (ADRB2).

44 (beta2AR) in wound scarring, the ability of beta 2 adrenergic receptor agonist (beta2ARag) to alter

45 ion (LOBP) with a regularly used long-acting beta(2)-adrenergic receptor agonist (LABA) is well docum

46 BDs) and reperfused with the addition of the beta(2)-adrenergic receptor agonist isoproterenol (iso),

47 chimeric TGF-beta type II receptor restored beta(2)-adrenergic receptor agonist-stimulated alveolar

48 ical mediator of acute lung injury, inhibits beta(2)-adrenergic receptor agonist-stimulated vectorial

49 cute asthma exacerbation is the short-acting beta(2)-adrenergic receptor agonist; however, there is v

50 Salmeterol (10 muM), a beta-2-adrenergic receptor agonist, significantly increa

51 lthough short-acting and long-acting inhaled beta(2)-adrenergic receptor agonists (SABA and LABA, res

52 ts supported encystation, whereas alpha- and beta(2)-adrenergic receptor agonists did not.

53 Exogenous or endogenous beta(2)-adrenergic receptor agonists enhance alveolar ep

54 Insulin stimulates Src to associate with the beta(2)-adrenergic receptor/AKAP250/protein kinase A/pro

55 Here we show that a mutant beta(2) adrenergic receptor and a mutant mu opioid recep

56 Recently, the structures of the beta(1) and beta(2) adrenergic receptors and the adenosine A(2a) rec

57 ergic receptor stimulation, markedly reduced beta(2)-adrenergic receptor and angiotensin II receptor

58 upon stimulation, whereas GPCRs such as the beta(2)-adrenergic receptor and CXCR4 are not capable of

59 The beta(2)-adrenergic receptor and delta opioid receptor re

60 lubilized a fusion protein consisting of the beta(2)-adrenergic receptor and green fluorescent protei

61 sine kinase Src regulates resensitization of beta(2)-adrenergic receptors and docks to gravin.

62 2 blocks the ability of insulin to sequester beta(2)-adrenergic receptors and the translocation of th

63 nents of this pathway, particularly PKA, the beta 2-adrenergic receptor, and BCAM/Lu, should be furth

64 ion of GRK5 by the PDGFRbeta, but not by the beta(2)-adrenergic receptor, and that by activating GRK5

65 gnaling of the ghrelin receptor, GPR119, the beta(2)-adrenergic receptor, and the neurokinin-1 recept

66 viously unreported dissimilar ligands of the beta(2)-adrenergic receptor, and the optimization of one

67 fused a cocktail of alpha(1)-, beta(1)-, and beta(2)-adrenergic receptor antagonists into the mPFC pr

68 ide blocked high affinity agonist binding to beta(2) adrenergic receptors (AR) and inhibited beta(2)A

69 Beta(1) and beta(2) adrenergic receptors (AR) regulate the intrinsic

70 current (I(Ca,L)) stimulated by beta(1)- or beta(2)-adrenergic receptor (AR) agonists in cat atrial

71 cromolecular signaling complex necessary for beta(2)-adrenergic receptor (AR) regulation of I(Ca,L).

72 es adenylate cyclase (AC)/cAMP and increases beta(2)-adrenergic receptor (AR) stimulation of L-type C

73 ve revealed that one of these receptors, the beta(2)-adrenergic receptor (AR), also couples to the in

74 We recently reported that beta(1)- and beta(2)-adrenergic receptors (AR) regulate the intrinsic

75 the cell surface targeting of alpha(2B)- and beta(2)-adrenergic receptors (AR).

76 reased BM noradrenergic innervation promotes beta(2)-adrenergic-receptor(AR)-interleukin-6-dependent

77 Both beta(1) and beta(2) adrenergic receptors are expressed in human and

78 on, many G protein-coupled receptors such as beta(2)-adrenergic receptors are internalized via beta-a

79 Crystal structures of engineered human beta 2-adrenergic receptors (ARs) in complex with an inv

80 Stimulation of beta(1)- and beta(2)-adrenergic receptors (ARs) in the heart results

81 ratinocytes (HOK) express the alpha(2B)- and beta(2)-adrenergic receptors (ARs).

82 rescence microscopy to visualize the FPR and beta(2)-adrenergic receptor as they internalized in the

83 We focused on the beta (2)-adrenergic receptor, as it is currently the rec

84 The beta(2)-adrenergic receptor (B2AR) and delta-opioid rece

85 LOBP has been attributed to beta(2)-adrenergic receptor (B2AR) downregulation, a pro

86 The prototypical beta-2 adrenergic receptor (B2AR) activates Galpha stimu

87 The beta-2 adrenergic receptor (B2AR) is well known to form

88 nvestigated this question by focusing on the beta-2 adrenergic receptor (B2AR), a G protein-coupled r

89 requirements to switch the recycling of the beta-2 adrenergic receptor (B2AR), a prototypic signalin

90 ined crystal structures of rhodopsin and the beta 2-adrenergic receptor (beta 2-AR) offer insight int

91 ng and predicting activation pathways of the beta 2-adrenergic receptor (beta 2-AR), folding of the F

92 C-terminal lysines to arginines in the human beta 2-adrenergic receptor (beta 2AR) (K348/372/375R).

93 Classically, the beta 2-adrenergic receptor (beta 2AR) and other members

94 The beta(2) adrenergic receptor (beta(2)AR) activation of Gs

95 undertaken to extend emerging evidence that beta(2) adrenergic receptor (beta(2)AR) agonists, in add

96 We have recently shown that Abeta binds to beta(2) adrenergic receptor (beta(2)AR) and activates pr

97 yl-terminal sequences NDSLL and EDSFL of the beta(2) adrenergic receptor (beta(2)AR) and platelet-der

98 Using the inactive structure of the human beta(2) adrenergic receptor (beta(2)AR) as a guide, we d

99 basal activation of the G protein Gs by the beta(2) adrenergic receptor (beta(2)AR) by using purifie

100 ansmembrane conductance regulator (CFTR) and beta(2) adrenergic receptor (beta(2)AR) can bind ezrinra

101 Agonist-induced ubiquitination of the beta(2) adrenergic receptor (beta(2)AR) functions as an

102 Recent experimental studies on the beta(2) adrenergic receptor (beta(2)AR) indicate that st

103 The beta(2) adrenergic receptor (beta(2)AR) is a prototypica

104 The beta(2) adrenergic receptor (beta(2)AR) is an archetypal

105 harmaceutical targets, and of the GPCRs, the beta(2) adrenergic receptor (beta(2)AR) is one of the mo

106 The beta(2) adrenergic receptor (beta(2)AR) signals through

107 id antibody fragment (nanobody) to the human beta(2) adrenergic receptor (beta(2)AR) that exhibits G

108 oplasmic end of transmembrane 6 (TM6) of the beta(2) adrenergic receptor (beta(2)AR), adjacent to the

109 DTRL present at the carboxyl termini of the beta(2) adrenergic receptor (beta(2)AR), the platelet-de

110 mation of a complex with agonist-bound human beta(2) adrenergic receptor (beta(2)AR).

111 y of AMPA receptors by a mechanism involving beta(2) adrenergic receptor (beta(2)AR).

112 glucagon receptor (GCGR; family B) with the beta(2) adrenergic receptor (beta(2)AR; family A).

113 Agonists of beta(2) adrenergic receptors (beta(2)AR) and glucocortic

114 y of constitutive GRK phosphorylation of the beta(2)-adrenergic receptor (beta 2AR), in vitro GRK pho

115 ort desensitization and sequestration of the beta(2)-adrenergic receptor (beta(2)-AR) and the angiote

116 Phosphorylation of the beta(2)-adrenergic receptor (beta(2)-AR) by protein kina

117 Polymorphisms of the beta(2)-adrenergic receptor (beta(2)-AR) can affect regu

118 reviously reported that association with the beta(2)-adrenergic receptor (beta(2)-AR) facilitates fun

119 -dependent pathway and degraded, whereas the beta(2)-adrenergic receptor (beta(2)-AR) failed to inter

120 anes from a HEK-293 cell line expressing the beta(2)-adrenergic receptor (beta(2)-AR) have been immob

121 Cellular expression of the beta(2)-adrenergic receptor (beta(2)-AR) is suppressed a

122 y upregulating a neuroprotective program via beta(2)-adrenergic receptor (beta(2)-AR) signaling and m

123 studies have indicated that some aspects of beta(2)-adrenergic receptor (beta(2)-AR) signaling are i

124 To determine whether beta(2)-adrenergic receptor (beta(2)-AR) stimulation con

125 the role of group-conserved residues in the beta(2)-adrenergic receptor (beta(2)-AR), amino acid rep

126 f the Galphas and Galphaq C termini with the beta(2)-adrenergic receptor (beta(2)-AR), targeted at th

127 of rhodopsin were replaced with those of the beta(2)-adrenergic receptor (beta(2)-AR).

128 Clenbuterol, a beta(2)-adrenergic receptor (beta(2)AR) agonist enhances

129 beta(2)-Adrenergic receptor (beta(2)AR) agonists are the

130 or by treatment with bronchodilators such as beta(2)-adrenergic receptor (beta(2)AR) agonists, indica

131 opic therapeutic expression, we utilized the beta(2)-adrenergic receptor (beta(2)AR) as a scaffold to

132 was constructed using the x-ray structure of beta(2)-adrenergic receptor (beta(2)AR) as the template.

133 denoviral-mediated overexpression of a human beta(2)-adrenergic receptor (beta(2)AR) cDNA increases b

134 have suggested that two polymorphisms of the beta(2)-adrenergic receptor (beta(2)AR) gene at codons 1

135 Although downregulation of the prototypical beta(2)-adrenergic receptor (beta(2)AR) has been extensi

136 s study, we investigated the significance of beta(2)-adrenergic receptor (beta(2)AR) in age-related i

137 19 nuclear magnetic resonance) labels in the beta(2)-adrenergic receptor (beta(2)AR) in complexes wit

138 Stimulation of the beta(2)-adrenergic receptor (beta(2)AR) in human embryon

139 messenger dynamics stimulated by endogenous beta(2)-adrenergic receptor (beta(2)AR) in living cells.

140 escale molecular dynamics simulations of the beta(2)-adrenergic receptor (beta(2)AR) in multiple wild

141 of structural segments stabilizing the human beta(2)-adrenergic receptor (beta(2)AR) in the absence a

142 ubiquitin ligase Mdm2 is critical for rapid beta(2)-adrenergic receptor (beta(2)AR) internalization.

143 Genetic variants at the beta(2)-adrenergic receptor (beta(2)AR) may modify asthm

144 Stimulation of CD86 and the beta(2)-adrenergic receptor (beta(2)AR) on a B cell, eit

145 Stimulation of the beta(2)-adrenergic receptor (beta(2)AR) on a CD40L/inter

146 orphic variant (beta(1)AR-Arg(389)), and the beta(2)-adrenergic receptor (beta(2)AR) or a loss-of-fun

147 displayed equivalent binding to recombinant beta(2)-adrenergic receptor (beta(2)AR) reconstituted in

148 ne the final composition of solutions of the beta(2)-adrenergic receptor (beta(2)AR) reconstituted wi

149 ar dynamics studies on ligand binding to the beta(2)-adrenergic receptor (beta(2)AR) suggested that l

150 coupled receptors and was validated with the beta(2)-adrenergic receptor (beta(2)AR) system.

151 For the beta(2)-adrenergic receptor (beta(2)AR) this requires ub

152 Agonist-stimulated beta(2)-adrenergic receptor (beta(2)AR) ubiquitination i

153 A human beta(2)-adrenergic receptor (beta(2)AR) was used to demo

154 al dynamics of the transmembrane core of the beta(2)-adrenergic receptor (beta(2)AR), a prototypical

155 beta(1)-adrenergic receptor (beta(1)AR), the beta(2)-adrenergic receptor (beta(2)AR), and the gamma-a

156 l, and biophysical properties of a GPCR, the beta(2)-adrenergic receptor (beta(2)AR), in high-density

157 BCR) and/or a neurotransmitter receptor, the beta(2)-adrenergic receptor (beta(2)AR), may cooperate t

158 Here we use the beta(2)-adrenergic receptor (beta(2)AR), the archetypal

159 Here, we show that the beta(2)-adrenergic receptor (beta(2)AR), the trimeric G(

160 m other G-protein-coupled receptors, such as beta(2)-adrenergic receptor (beta(2)AR), which internali

161 itutions at Glu122(3.41) in the well-studied beta(2)-adrenergic receptor (beta(2)AR), which was predi

162 HASM significantly attenuated isoproterenol (beta(2)-adrenergic receptor (beta(2)AR)-mediated)- and 5

163 tiating clathrin-mediated endocytosis of the beta(2)-adrenergic receptor (beta(2)AR).

164 ts as a positive allosteric modulator of the beta(2)-adrenergic receptor (beta(2)AR).

165 semble of conformers of a prototypical GPCR, beta(2)-adrenergic receptor (beta(2)AR).

166 -like modifier 1 (SUMO-1) upon activation of beta(2)-adrenergic receptor (beta(2)AR).

167 s the primary Gi/o-coupling receptor and the beta(2)-adrenergic receptor (beta(2)AR, which primarily

168 stribution, dynamics, and trafficking of the beta(2)-adrenergic receptor (beta(2)AR; a type A recepto

169 ry G protein Galpha(s), such as beta(1)- and beta(2)-adrenergic receptors (beta(1)ARs and beta(2)ARs)

170 beta(2)-adrenergic receptors (beta(2)-AR) are low abunda

171 beta(2)-Adrenergic receptors (beta(2)-ARs) are low abund

172 ow that at low concentrations of an agonist, beta(2)-adrenergic receptors (beta(2)-ARs) signal throug

173 lae, including redistribution of sarcolemmal beta(2)-adrenergic receptors (beta(2)AR) and localized s

174 Although beta(2)-adrenergic receptors (beta(2)AR) are expressed o

175 beta(2)-adrenergic receptors (beta(2)AR) of all species

176 c (M2R), D1 (D1R) and D2 (D2R) dopamine, and beta(2)-adrenergic receptors (beta(2)AR) was assessed us

177 Recent studies demonstrated that beta(2)-adrenergic receptors (beta(2)ARs) colocalize wit

178 zation between prostaglandin E receptors and beta(2)-adrenergic receptors (beta(2)ARs) in airway smoo

179 beta(2)-Adrenergic receptors (beta(2)ARs) regulate cellu

180 Lysosomal degradation of ubiquitinated beta(2)-adrenergic receptors (beta(2)ARs) serves as a ma

181 eptors and diminished relaxation mediated by beta(2)-adrenergic receptors (beta(2)ARs).

182 iated phosphorylation and desensitization of beta(2)-adrenergic receptors (beta(2)ARs).

183 sible single amino acid substitutions to the beta-2 adrenergic receptor (beta(2)AR) at four concentra

184 tance regulator (CFTR) chloride channel, the beta-2 adrenergic receptor (beta(2)AR), and fractions of

185 mediated via beta-agonist stimulation of the beta-2-adrenergic receptor (beta 2AR).

186 4, BclII modifying factor, phospholipase C, beta 2, adrenergic receptor, beta 1, actin-binding LIM p

187 Beta(2)-adrenergic receptor (beta2-AR) is a susceptibili

188 A chemical biology approach identifies a beta 2 adrenergic receptor (beta2AR) agonist ARA-211 (Pi

189 To investigate the role of the beta 2 adrenergic receptor (beta2AR) in wound scarring,

190 Three haplotypes found in the beta 2-adrenergic receptor (beta2AR) gene and characteri

191 The beta-2 adrenergic receptor (beta2AR) agonist formoterol

192 pathology, we removed the gene encoding the beta-2 adrenergic receptors (beta2ARs) from a mouse mode

193 as, we used an active-state structure of the beta(2)-adrenergic receptor (beta2R) to build beta2R-WT

194 The human beta(2)-adrenergic receptor (betaAR) is rapidly desensit

195 This was inhibited by a beta(2)-adrenergic receptor blocker and by an inhibitor

196 ulation that could be rescued by a selective beta(2)-adrenergic receptor blocker and developed sustai

197 dynamics characterization of the GPCR human beta(2) adrenergic receptor bound to the inverse agonist

198 ay can be used to identify ligand binding to beta(2)-adrenergic receptors, but also the downstream re

199 of the C-terminal cytoplasmic domain of the beta(2)-adrenergic receptor by Akt in vitro identified S

200 413) competes readily for the binding of the beta(2)-adrenergic receptor by gravin, both using in vit

201 the ligand-induced conformational changes in beta(2)-adrenergic receptor by ligands of varied efficac

202 l that gravin binds the receptor through the beta(2)-adrenergic receptor C-terminal cytoplasmic domai

203 ion of the following genes: 5-HT 1c, 5-HTR7, beta 2 adrenergic receptor, c-Fgr, collagen 10 alpha 1,

204 By using a hybrid beta(2)-adrenergic receptor-C-X-C chemokine receptor typ

205 naling pathways in bovine rhodopsin or human beta(2)-adrenergic receptor can be mediated by specific

206 Different conformations of the beta(2) adrenergic receptor cause quenching of the bound

207 nactivation in response to inhibition of the beta(2)-adrenergic receptor causes Galpha(s) to move bac

208 e to stimulation of an exogenously expressed beta(2)-adrenergic receptor causes Galpha(s) to move fro

209 prevented functional resensitization of the beta(2)-adrenergic receptor, converting the temporal pro

210 egulation of membrane proteins including the beta(2)-adrenergic receptor, cystic fibrosis transmembra

211 and the C-terminal cytoplasmic domain of the beta(2)-adrenergic receptor demonstrate that the tyrosin

212 ional analysis using x-ray structures of the beta(2)-adrenergic receptor demonstrated that PheVI:09 (

213 on, the C-terminal cytoplasmic domain of the beta(2)-adrenergic receptor demonstrates a potent inhibi

214 In contrast, beta 2-adrenergic receptor desensitization was significa

215 p 2, not observed in either rhodopsin or the beta(2)-adrenergic receptor, directly interacts by means

216 tein kinase A (PKA) signaling pathway by the beta(2) adrenergic receptor (encoded by ADRB2).

217 ary for GRK5-mediated phosphorylation of the beta(2)-adrenergic receptor, even though beta(2)-adrener

218 are involved in translational suppression of beta(2)-adrenergic receptor expression.

219 (S/T)XL, the optimal C-terminal motif in the beta(2)-adrenergic receptor for EBP50/NHERF binding.

220 compounds in a challenging way, we chose the beta(2)-adrenergic receptor, for which a large number of

221 ate of receptor loss, effectively protecting beta 2-adrenergic receptor from down-regulation even aft

222 l sequence-dependent recycling receptor, the beta-2 adrenergic receptor, from bulk recycling proteins

223 PA/Galpha(13)/p115RhoGEF/RhoA pathway to the beta(2)-adrenergic receptor/Galpha(s)/adenylyl cyclase p

224 tion, and metabolic disorders, including the beta(2)-adrenergic receptor gene ADRB2 and the glucocort

225 Genetic variation in the beta-2 adrenergic receptor gene (ADRB2) has been implica

226 beta(2)-Adrenergic receptor GFP bound to dihydroalprenol

227 equently, the binary complex of agonist with beta(2)-adrenergic receptor GFP.

228 A(2A) adenosine receptor and the beta(1) and beta(2) adrenergic receptors have shown important differ

229 receptors (GPCRs), such as rhodopsin and the beta(2) adrenergic receptor, have provided a picture of

230 blocks insulin-induced sequestration of the beta(2)-adrenergic receptor, implicating Akt in downstre

231 port the crystal structure of the prototypic beta(2)-adrenergic receptor in complex with an orthoster

232 f internalization and down-regulation of the beta(2)-adrenergic receptor in response to treatment of

233 , and these effects required the presence of beta(2)-adrenergic receptors in microglia.

234 reagent onto the extracellular domain of the Beta-2 adrenergic receptor in HEK293T cells, followed by

235 serve that expression of increased levels of beta(2)-adrenergic receptor increasingly inhibits insuli

236 V(2)R(inh)-02 did not inhibit forskolin or beta(2)-adrenergic receptor-induced cAMP production and

237 ant pathway as they bind to the beta(1)- and beta(2)-adrenergic receptors, initially making contact w

238 ominant-negative K44A dynamin, inhibits both beta(2) adrenergic receptor internalization and bacteria

239 T382A or T382V) states of arrestin-3 promote beta(2)-adrenergic receptor internalization and bind cla

240 s insulin action on cyclic AMP responses and beta(2)-adrenergic receptor internalization.

241 in HEK293 cells and significantly attenuated beta(2)-adrenergic receptor internalization.

242 ed to monitor the incorporation of the human beta(2)-adrenergic receptor into a solid-supported egg p

243 gic receptor and binding of carazolol to the beta(2)-adrenergic receptor involve similar interactions

244 However, when the beta(2) adrenergic receptor is bound to a full agonist,

245 emory consolidation because signaling by the beta(2)-adrenergic receptor is redundant with signaling

246 Its ability to bind and desensitize the beta(2)-adrenergic receptor is, however, unaltered.

247 y that has previously not been described for beta (2)-adrenergic receptor ligands, and one of them sh

248 e QRET and the PathHunter methods a panel of beta(2)-adrenergic receptor ligands (epinephrine, terbut

249 the fusion protein and, in competition with beta(2)-adrenergic receptor ligands, K(d) values for ago

250 oted desensitization of airway smooth muscle beta-2-adrenergic receptors, mediated by G protein-coupl

251 In the beta(2) adrenergic receptor, mutation of Cys(6.47) to Th

252 esion to laminin, mediated primarily via the beta 2-adrenergic receptor, occurred in SS RBC samples f

253 e recently determined X-ray structure of the beta(2)-adrenergic receptor offers an opportunity to inv

254 ell known and include phosphorylation of the beta(2)-adrenergic receptor on Tyr(350), Tyr(354), and T

255 e neurotransmitter norepinephrine stimulates beta(2)-adrenergic receptors on B lymphocytes to promote

256 ich induces hyperalgesia by direct action at beta(2)-adrenergic receptors on primary afferent nocicep

257 ligands, such as the carboxyl-termini of the beta(2)-adrenergic receptor or the platelet-derived grow

258 in, engineered A(2A)-adenosine, beta(1)- and beta(2)-adrenergic receptors, permits comparative analys

259 binding to physiological targets, including beta(2)-adrenergic receptor, platelet-derived growth fac

260 Isoproterenol stimulation of the beta(2)-adrenergic receptor promotes dephosphorylation o

261 Pharmacologic stimulation of beta(2)-adrenergic receptors recapitulated these observa

262 Interestingly, although beta 2-adrenergic receptor resensitization was potently

263 Blockade of beta(2)-adrenergic receptor sequestration does not alter

264 l role in this process and the importance of beta(2)-adrenergic receptor signaling.

265 renin angiotensin aldosterone signaling and beta-2 adrenergic receptor signaling.

266 Thus, arrestins are selective regulators of beta-2-adrenergic receptor signaling and function in air

267 hat mutants support rapid internalization of beta 2-adrenergic receptor similar to wild type arrestin

268 Three predicted mutations in beta(2)-adrenergic receptor stabilize binding of noncogn

269 cyclase, RGS2 inhibited Galpha(s)-Q227L- or beta(2)-adrenergic receptor-stimulated cAMP accumulation

270 beta(2)-adrenergic receptor stimulation by epinephrine c

271 s to enhanced cAMP generation in response to beta(2)-adrenergic receptor stimulation, markedly reduce

272 lar modeling analysis of FFA2 based on human beta(2)-adrenergic receptor structure revealed potential

273 lead-like" molecules were docked against the beta(2)-adrenergic receptor structure.

274 od vessels from mice lacking beta(1)- and/or beta(2)-adrenergic receptor subtypes (beta(1)-KO, beta(2

275 dea that PKA-mediated phosphorylation of the beta(2)-adrenergic receptor switches its predominant cou

276 ize a 1.02 mus all-atom simulation of an apo-beta(2) adrenergic receptor that is missing the third in

277 Herein, we map the regions of the beta(2)-adrenergic receptor that are required for bindin

278 In contrast, cardiac fibroblasts express beta(2)-adrenergic receptors that activate ERK through a

279 lated and unphosphorylated agonist-activated beta 2-adrenergic receptor to manipulate the receptor-ar

280 uestration does not alter the ability of the beta(2)-adrenergic receptor to potentiate insulin action

281 ulin to phosphatidylinositol 3-kinase and to beta(2)-adrenergic receptor trafficking.

282 Reversal of beta(2)-adrenergic receptor translational repression by

283 ecular signaling complexes that comprise the beta(2) adrenergic receptor, trimeric G(s) protein, aden

284 olecular signaling complex consisting of the beta(2) adrenergic receptor, trimeric G(s) protein, and

285 beta(1)- and beta(2)-adrenergic receptors utilize different signaling

286 s is stimulated by sympathetic activation of beta(2)-adrenergic receptors via adrenal catecholamines,

287 The beta(2) adrenergic receptor was found to be directly ass

288 l of the A(2A) AR and was rectified when the beta(2)-adrenergic receptor was used as a template for h

289 or internalization, while the endocytosis of beta(2)-adrenergic receptors was completely prevented.

290 r interactions of fenoterol analogs with the beta(2)-adrenergic receptor, we developed a new agonist

291 e studies of the conformations of the intact beta(2) adrenergic receptor were performed in solution.

292 nes with alpha(1)-, alpha(2)-, beta(1)-, and beta(2)-adrenergic receptors were examined.

293 beta(1)- and beta(2)-Adrenergic receptors were found on both epitheli

294 ty of lysophosphatidic acid to sequester the beta(2)-adrenergic receptor, whereas expression of const

295 carboxyl-terminal cytoplasmic domain of the beta(2)-adrenergic receptor, which engages in PDZ domain

296 r of the PICK1-binding DAT C terminus to the beta(2)-adrenergic receptor, which sorts to recycling up

297 for agonist-promoted internalization of the beta(2)-adrenergic receptor, while arrestin/beta(2)-adap

298 pectively, of a single active human chimeric beta(2)-adrenergic receptor with the C-terminal tail of

299 f sequential ligand binding exhibited by the beta(2)-adrenergic receptor, with the former interaction

300 f two GPCRs: the V2 vasopressin receptor and beta-2 adrenergic receptor, without affecting endocytosi